Replies to post #3261 on GeoVax Labs Inc (GOVX)

[headsortails2066]

GOVX Is Certainly For Real

I agree ... this company is invested in quite a few things.

Their burn rate is fine since they receive millions from grants to help their funding.

One day ... not sure which ... but GOVX will catch the eye of the investment world.

With less than 40 million in float this is being held tight right now.

[InforichIH]

With the Zika news I agree that investors will look for a solid Zika-related stock. Not a scam stock, for sure.

As a LT holder of GOVX I have been attracted by their approach and prospects but disappointed so far by the results.

Maybe the lack of our stock pps rise some expected is due to the competition. How fast can GOVX move to compete? For example:

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada

PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health Canada’s Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.

This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device, Inovio’s proprietary intradermal DNA delivery device. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses - the immune responses necessary to fight viral infections - in small and large animal models.